Latham & Watkins Advises the Underwriters on Nanox’s Initial Public Offering

A capital markets team advised the underwriters on the innovative medical imaging technology company’s offering.

August 26, 2020

Nano-X Imaging LTD, an innovative medical imaging technology company, has announced the closing of its initial public offering of 10,555,556 ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,376,812 additional ordinary shares at a public offering price of US$18.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, were US$190.0 million. All of the shares were offered by Nanox. The shares began trading on the Nasdaq Global Market under the ticker symbol “NNOX” on August 21, 2020. 

Latham & Watkins LLP represents the underwriters in the transaction with a corporate deal team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, Danny Shulman, and Tyler Vivian. Advice was also provided on FDA regulatory matters by partner Ben Haas, with associate Chad Jennings; on healthcare regulatory matters by counsel Betty Pang; on tax matters by partner Jocelyn Noll, with associate Michael Yu; on intellectual property matters by partner Alan Tamarelli, with associate Seth Appiah-Opoku; and on data privacy/security matters by counsel Heather Deixler.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.